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Background: Although increasing evidence has indicated that brain insulin dysfunction is a risk factor for
Alzheimer disease (AD), the underlying mechanisms by which insulin deficiency may impact the development of
AD are still obscure. Using a streptozotocin (STZ)-induced insulin deficient diabetic AD transgenic mouse model,
we evaluated the effect of insulin deficiency on AD-like behavior and neuropathology.
Results: Our data showed that administration of STZ increased the level of blood glucose and reduced the level of
serum insulin, and further decreased the phosphorylation levels of insulin receptors, and increased the activities of
glycogen synthase kinase-3a/b and c-Jun N-terminal kinase in the APP/PS1 mouse brain. We further showed that
STZ treatment promoted the processing of amyloid-b (Ab) precursor protein resulting in increased Ab generation,
neuritic plaque formation, and spatial memory deficits in transgenic mice.
Conclusions: Our present data indicate that there is a close link between insulin deficient diabetes and cerebral
amyloidosis in the pathogenesis of AD.
Background
Alzheimer’s disease (AD) is a neurodegenerative disease
clinically characterized by progressive cognitive impair-
ment, and pathologically characterized by the presence of
extracellular senile plaques and intracellular neurofibrillary
tangles (NFTs) in the brain. Senile plaques are largely
composed of amyloid-b (Ab), which is a 4 kDa peptide
derived from the amyloid-b precursor protein (APP).
Processing of APP involves two major pathways, one
non-amyloidogenic and one amyloidogenic. The non-
amyloidogenic pathway is mediated by a-a n dg-secretases
and gives rise to a large fragment known as soluble APPa
(sAPPa)a n das m a l l3k D ap e p t i d ep 3 .O nt h eo t h e r
hand, the amyloidogenic pathway is mediated by b-a n d
g-secretases and produces soluble APPb (sAPPb)a n dA b
[1-3]. Ab i st o x i ct on e u r o n s ,a n dt h ed e p o s i t i o no fA b
and subsequent formation of senile plaques are considered
to be the primary cause of AD [4].
The pancreatic b-cell-secreted hormone, insulin, pre-
dominantly acts by reducing blood sugar levels. Many
studies have shown that both insulin and its target, insu-
lin receptors (IR), are abundantly distributed throughout
the brain and are involved in the regulation of glucose
metabolism, food intake, and body weight [5]. Insulin
also affects numerous brain functions including cognition
and memory through complex insulin/IR signaling path-
ways [6]. Importantly, increasing evidence has indicated
that brain insulin dysfunction is related to late onset AD
[7]. First, AD patients present with reduced CSF insulin
levels and impaired insulin-like signal transduction, com-
pared with age-matched controls [8,9]. Second, AD
patients with lower insulin levels have lower cognitive
skills than those with normal insulin levels [10]. Third,
disruption of cerebral IR functions by intracerebroventri-
cular (icv) injection of streptozotocin (STZ), leads to AD-
like changes and progressive cognitive impairment in an
AD transgenic mouse model [11]. By contrast, icv admin-
istration of insulin improves memory formation in a pas-
sive-avoidance task in rats [12]. Most interestingly, recent
clinical evidence suggests that diabetic patients treated
with insulin may not develop AD [13,14]. Intranasal
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the cognitive function without the risk of peripheral
hypoglycemia in human [15,16]. Administration of insu-
lin and glucose enhances the memory of AD patients to a
greater extent than injection of glucose alone [17].
Furthermore, depletion of insulin by administration of
STZ causes markedly increased levels of phosphorylated
tau (p-tau) in the mouse brain [18,19], and increased
levels of Ab in the mouse brain [20], suggesting that
insulin deficiency is involved in tau phosphorylation and
Ab generation. However, the mechanisms responsible for
the effects of insulin deficiency on AD pathogenesis
remain largely unknown.
In the present study, we evaluated the effect of insulin
deficiency on APP processing and Ab generation using
an APP/presenilin-1 (APP/PS1) double transgenic
mouse model treated with STZ. Our results indicate
that insulin deficiency reduces IR phosphorylation, pro-
motes APP processing, accelerates cerebral amyloidosis
and exacerbates spatial memory deficits in these trans-
genic mice. The present data underscore the potential
role of insulin deficiency in the pathogenesis of AD.
Results
High blood glucose and low serum insulin levels in
STZ-treated APP/PS1 mice
The body weight and blood glucose of the APP/PS1 mice
were measured at week 1, 4, 8, 12, 16 and 20 after STZ
administration. As time increased, the body weights were
gradually decreased in STZ-treated mice, but increased in
age-matched controls. STZ-treated mice had lower body
weights from week 12 to 20, compared with vehicle con-
trols (Figure 1A; p < 0.05). Blood glucose levels of STZ-
treated mice gradually increased with time, but no signifi-
cant changes were observed in the controls. STZ-treated
mice had higher levels of blood glucose from week 1 to
20, compared with vehicle controls (Figure 1B; p < 0.01).
To determine whether STZ treatment reduced the pan-
creatic insulin secretion in APP/PS1 mice, the serum
insulin levels were examined at the 20th week after STZ
administration. The levels of insulin were 0.49 ± 0.24
mU/L in STZ-treated mice and 1.30 ± 0.29 mU/L in
vehicle controls, respectively (Figure 1C). Statistical ana-
lysis showed that there was a 62% reduction in the serum
insulin level of STZ-induced diabetic APP/PS1 mice,
compared with vehicle controls (Figure 1C; p < 0.05).
Insulin deficiency reduces insulin receptor
phosphorylation in the APP/PS1 mouse brain
Insulin binding to its receptor IR and its subsequent
dimerization and autophosphorylation is the initial step
in activation of the insulin/IR signaling pathways [21].
In the brain, the phosphorylation levels of IR represent
the activity of IR protein. Thus, we examined the levels
of both total IR protein and phosphorylated IR (p-IR),
to evaluate the effects of insulin deficiency on IR activity
in the STZ-induced diabetic APP/PS1 mouse brain. As
shown in Figure 2, immunoblotting results showed that
the level of total IR protein was not affected by STZ-
induced insulin deficiency (Figure 2A and 2B; p > 0.05).
However, the level of p-IR was significantly reduced by
52% in the STZ-treated mouse brain, compared with
vehicle control (Figure 2A and 2C; p < 0.01). Further,
the ratio of p-IR/IR was also markedly decreased by 63%
in the STZ-treated mouse brain (Figure 2D; p < 0.01).
Effects of insulin deficiency on GSK3, ERK and JNK
phosphorylation in the APP/PS1 mouse brain
To determine whether STZ treatment influences the
activities of the downstream molecules in the IR-
mediated signaling pathway, western blot analyses were
employed to assess the expression levels of GSK3, ERK
and JNK (Figure 3), which have been previously shown
to be associated closely with Ab generation and senile
plaque formation [22-24]. The expression levels of both
total proteins and phosphorylated forms of GSK3a,
GSK3b, ERK and JNK were analyzed (Figure 3A, D and
3F). STZ treatment significantly reduced the level of
p-GSK3a (Figure 3B; p < 0.01), whereas the total pro-
tein level remained unchanged (Figure 3B; p > 0.05).
T h u s ,t h er a t i oo fp - G S K 3 a/GSK3a was significantly
reduced by 50% in STZ-induced diabetic mice compared
with controls (Figure 3B; p < 0.01). Similarly, the expres-
sion level of p-GSK3b was reduced, and the ratio of
p-GSK3b/GSK3b was significantly reduced by 49% in
STZ-induced diabetic mice (Figure 3C; p < 0.05). STZ
treatment led to a decrease in the ratio of p-ERK/ERK
by 24%, but this was not statistically significant, com-
pared with the vehicle control (Figure 3E; p > 0.05).
Furthermore, activation of the JNK signaling pathway
was detected in the STZ-treated mouse brain, and the
ratio of p-JNK1/JNK1 and p-JNK2/JNK2 was increased
by 118% and 89%, respectively, compared with the vehi-
c l ec o n t r o l( F i g u r e3 Ga n d3 H ;p<0 . 0 1 ) .T a k e n
together, these data suggest that insulin deficiency
reduces the phosphorylation of GSK3a/b, enhances the
phosphorylation of JNK1/2, and, thus, increases GSK3
and JNK activities in STZ-treated APP/PS1 mouse brain.
Insulin deficiency enhances APP processing in the
APP/PS1 mouse brain
GSK3 and JNK have been known to affect Ab genera-
tion by modulation on APP processing [25,26]. To ver-
ify the effects of STZ treatment on APP processing, we
measured the expression levels of APP mRNA and
APP695 protein in APP/PS1 mouse brain (Figure 4).
RT-PCR results showed that there were no signifi-
cant differences in levels of APP mRNA between
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Page 2 of 13Figure 1 The body weight, blood glucose and serum insulin levels in APP/PS1 mice. APP/PS1 mice were injected intraperitoneally with
STZ (90 mg/kg) for 2 consecutive days, while age-matched control APP/PS1 mice received citrate buffer only. (A) The changes in body weight
in vehicle controls and STZ-induced diabetic APP/PS1 mice. From week 12 to 20 after STZ treatment, the body weights of STZ-treated mice
were lower than those of the vehicle controls. (B) The levels of blood glucose in controls and STZ-treated APP/PS1 mice. From week 1 to 20,
STZ treatment significantly increased the levels of blood glucose, compared with controls. (C) At the 20th week after STZ treatment, the serum
insulin level was measured. A significant reduction in serum insulin levels could be detected in STZ-induced diabetic APP/PS1 mice, compared
with vehicle control mice. *p < 0.05; **p < 0.01 (n = 7).
Figure 2 Administration of STZ downregulates the phosphorylation levels of IR. (A) Western blots showing the expression levels of
phosphorylated insulin receptor (p-IR) and total IR proteins in APP/PS1 transgenic mouse brain 20 weeks after STZ administration. b-actin was
used as a loading control. (B) There were no significant differences in total IR levels between vehicle controls and STZ-treated mice. (C) Insulin
deficiency induced by STZ administration led to a marked reduction in the p-IR level in the transgenic mouse brain. (D) The ratio of p-IR/IR was
significantly reduced in STZ-treated mouse brain, compared with the vehicle control. **p < 0.01 (n = 7).
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Page 3 of 13Figure 3 Expression levels of GSK, ERK and JNK in the APP/PS1 mouse brain 20 weeks after STZ treatment. (A) Immunoblot analyses
showing the protein levels of GSK-3a and GSK-3b in transgenic mouse brain. b-actin was used as a loading control. (B) A marked reduction in
p-GSK3a level was detected in STZ-treated mouse brain. Also the ratio of p-GSK3a/GSK3a was significantly reduced after STZ treatment. (C)
Insulin deficiency reduced GSK3b phosphorylation, and resulted in a reduced ratio of p-GSK3b/GSK3b in STZ-induced diabetic mouse brain. (D)
Immunoblot analyses showing the expression levels of ERK in transgenic mouse brain. b-actin was used as a loading control. (E) Administration
of STZ resulted in a reduced ratio of p-ERK/ERK, but this was not statistically significant compared with the vehicle control. (F) Immunoblot
analyses showing the expression levels of JNK in transgenic mouse brain. b-actin was used as a loading control. (G) STZ treatment increased
JNK1 phosphorylation and the ratio of p-JNK1/JNK1 was significantly increased in STZ-induced diabetic mouse brain. (H) The expression levels of
p-JNK2 and the ratio of p-JNK2/JNK2 were significantly increased in STZ-induced diabetic mouse brain. *p < 0.05, **p < 0.01 (n = 7).
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Page 4 of 13STZ-treated mouse brain and control (Figure 4A and
4B; p > 0.05). However, immunoblot analysis revealed
that STZ treatment increased the level of APP695 pro-
tein by 98%, compared with the control (Figure 4C
a n d4 D ;p<0 . 0 1 ) .
We then measured the activities of a-, b- and g-secre-
tase in response to insulin deficiency using antibodies
against ADAM10, BACE1 and PS1, respectively (Figure
4E). The results obtained showed no detectable changes
for the ADAM10 and PS1 (Figure 4F and 4H; p > 0.05).
However, the level of BACE1 was significantly increased
by 122% in the insulin-deficient mouse brain relative to
the control (Figure 4G; p < 0.01).
Next, we measured the expression levels of APP clea-
vage fragments that are important to explain the produc-
tion of Ab, including sAPPa,s A P P b and CTFs, in the
brain samples of APP/PS1 mice (Figure 4I). Insulin defi-
ciency reduced the expression level of sAPPa by 58%
(Figure 4J; p < 0.01), and increased the levels of sAPPb by
71% (Figure 4K; p < 0.01). Western blot analysis using an
anti-CTFs antibody showed a significant 84% increase in
the production of CTFs in STZ-induced diabetic mice
relative to vehicle controls (Figure 4L; p < 0.05).
Taken together, these results suggest that insulin defi-
ciency regulates the amyloidogenic processing of APP in
the APP/PS1 transgenic mouse brain.
Figure 4 Expression levels of APP, cleavage enzymes and fragments of APP in STZ-treated transgenic mouse brain. (A) RT-PCR analysis
was performed to determine the levels of APP mRNA in APP/PS1 transgenic mouse brain. GAPDH was used as an internal reference gene. (B)
There were no significant differences in expression levels of APP mRNA between in the STZ- and vehicle-treated transgenic mouse brain. (C)
Immunoblotting showing the expression levels of APP695 in vehicle control and STZ-treated APP/PS1 transgenic mouse brain. b-actin was used
as a loading control. (D) Administration of STZ significantly increased the expression level of APP695 in the transgenic mouse brain. (E)
Immunoblotting showing the expression levels of ADAM10, BACE1, PS1 in transgenic mouse brain. b-actin was used as a loading control. (F) STZ
treatment did not affect the expression level of ADAM10 protein. (G) STZ-induced insulin deficiency resulted in a marked increase in BACE1
protein in the transgenic mouse brain. (H) STZ treatment resulted in an increased level of PS1 protein, but the difference was not statistically
significant, compared with the vehicle control. (I) Immunoblotting showing the expression levels of sAPPa, sAPPb and CTFs in transgenic mouse
brain. b-actin was used as a loading control. (J) STZ-induced insulin deficiency significantly reduced the levels of sAPPa. (K) STZ treatment
resulted in a markedly increased level of sAPPb in transgenic mouse brain. (L) STZ treatment significantly increased the level of CTFs. *p < 0.05,
**p < 0.01 (n = 7).
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APP/PS1 mice
To investigate the effect of insulin deficiency on Ab
deposition and senile plaque formation, sections from
vehicle- and STZ-treated APP/PS1 mouse brains were
stained with an antibody against Ab. In general, Ab-
immunoreactive plaques were distributed throughout the
cortex and hippocampus in both vehicle- and STZ-treated
APP/PS1 mouse brain. However, both the number and
size of the Ab-immunoreactive senile plaques were mark-
edly increased in the cortex and hippocampus in the STZ-
treated mouse brain (Figure 5A). Image analyses showed a
significant effect of insulin deficiency on Ab neuropathol-
ogy. Quantitative analysis of the plaque numbers showed a
26% increase in the cortex and a 62% increase in the hip-
pocampus, respectively (Figure 5B). Changes in Ab burden
were also analyzed by measuring the areas of neuritic pla-
ques in vehicle- and STZ-treated APP/PS1 mouse brain.
In STZ-treated mice, the area of Ab plaques was signifi-
cantly increased by 1.5-fold in the cortex and by 2-fold in
the hippocampus, respectively (Figure 5C). Levels of
Ab1-42 in STZ-induced diabetic APP/PS1 mouse brains
were also measured by Sandwich ELISA. Ab1-42 levels
were markedly increased in STZ-treated APP/PS1 mice
relative to controls (12.63 ± 1.97 pg/mg vs. 18.30 ±
1.60 pg/mg, p < 0.01) (Figure 5D).
Insulin deficiency exacerbates cognitive impairment in
STZ-induced APP/PS1 diabetic mice
To investigate whether insulin deficiency affects learning
and memory in STZ-treated APP/PS1 mice, behavioral
tests were performed at 19 weeks after STZ treatment.
In the visible platform test, we observed that STZ-
induced diabetic mice and vehicle controls had a similar
escape latency (50.65 ± 5.18 vs. 48.07 ± 6.65; Figure 6A;
p > 0.05) and path length (0.99 ± 0.23 vs. 0.90 ± 0.19;
Figure 6B; p > 0.05), indicating that STZ-induced insulin
deficiency did not affect the motility or vision in our
mouse model. In the place navigation (hidden platform)
tests, STZ-treated APP/PS1 mice spent more time
searching for the hidden platform than vehicle controls.
From the 2nd to 5th day, the escape latencies of STZ-
induced diabetic mice and controls were 58.62 ± 2.61
vs. 51.04 ± 5.34 (p < 0.05), 53.81 ± 4.15 vs. 46.44 ± 3.05
(p < 0.05), 54.26 ± 3.35 vs. 41.60 ± 4.16 (p < 0.01),
51.45 ± 4.67 vs. 36.60 ± 3.13 (p < 0.01), respectively
(Figure 6C). The path length of STZ-treated mice and
vehicle controls was 1.06 ± 0.09 vs. 0.94 ± 0.05 (p <
0.01), 0.98 ± 0.08 vs. 0.60 ± 0.12 (p < 0.01), 0.96 ± 0.05
vs. 0.62 ± 0.11 (p < 0.01), 0.92 ± 0.07 vs. 0.51 ± 0.07
(p < 0.01), respectively (Figure 6D). Moreover, in the
probe trial on the last day of testing, the STZ-treated
mice passed the former platform location significantly
fewer times than the controls (1.60 ± 0.55 vs. 3.80 ±
0.84; Figure 6E; p < 0.05). Overall, these behavioral tests
indicate that STZ-induced diabetic APP/PS1 mice show
significant cognitive deficits in spatial learning and
memory function.
Discussion
The accumulating evidence that a lower expression of
insulin and insulin receptors occurs in the brain of AD
suggests a role of impaired insulin signaling pathway in
the pathogenesis of AD [27,28]. Several epidemiological
and experimental studies have demonstrated that
impaired insulin and insulin signaling transduction
occur in both diabetes mellitus and AD, suggesting a
linkage between these two disorders [29-32]. In the pre-
sent study, a mouse model of combined insulin-deficient
diabetes and AD was made by injecting APP/PS1 trans-
genic mice with STZ, a known toxin for pancreatic insu-
lin-producing b-cells. We found that administration of
STZ markedly increased the level of blood glucose and
reduced the level of serum insulin. Thus, we used this
model to assess whether insulin deficiency exacerbated
cerebral amyloidosis and behavioral deficits, and to
explore the underlying mechanisms.
Consistent with previous reports, our findings showed
that insulin deficient diabetes induced by STZ exacer-
bated the accumulation of Ab in APP/PS1 transgenic
mice [33]. First, a marked increase in APP695 suggests
that the processing of APP by the non-amyloidogenic
pathway is highly impaired, which is further confirmed
by the very low levels of sAPPa. Since the non-amyloido-
genic pathway is the major pathway for APP processing,
an impaired a-cleavage explains the increased levels of
APP without apparent increased transcription. Second,
we observed that insulin deficiency enhanced the BACE1
expression and the sAPPb fragment, resulting in
increased soluble Ab.T h i r d ,i m m u n o b l o ta n a l y s i s
showed a significant increase in the C-terminal fragments
of amyloid precursor protein (APP-CTFs) in STZ-
induced diabetes. APP-CTFs are the substrates of g-
secretase and are also the direct precursor of Ab [34,35].
Therefore, the increased expression levels of APP-CTFs
could also be responsible for the Ab accumulation.
Insulin is a polypeptide hormone consisting of a 21-
amino acid a chain linked to a 30-amino acid b chain
by two disulphide bonds [36]. It is synthesized primarily
by b-cells of the pancreatic islets of Langerhans, and
predominantly acts by reducing blood sugar levels in the
periphery. In addition, insulin can be partially formed in
the hippocampus, prefrontal cortex, entorhinal cortex,
and the olfactory bulb [37]. In the brain, insulin exerts
its pleiotropic effects through binding to its receptors
and forms the insulin/IR complex [38], and triggers the
IR to undergo dimerization and autophosphorylation
[39]. The phosphorylated or active IR is involved in the
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Page 6 of 13Figure 5 STZ-induced insulin deficiency accelerates plaque formation and Ab secretion in the APP/PS1 mouse brain. (A) Twenty weeks
after STZ administration, the senile plaques were detected using Ab immunohistochemistry, and Ab levels were measured by ELISA in APP/PS1
transgenic mouse brain. The representative images of Ab-immunostained brain sections from vehicle control and STZ-treated transgenic mice,
respectively. Note the number and size of Ab-positive plaques were increased in the cortex and hippocampus in STZ-treated mice, compared
with the control. Scale bar = 100 μm. (B) STZ-induced insulin deficiency significantly increased the number of plaques in the cortex and
hippocampus in the transgenic mouse. (C) Insulin deficiency led to an increase in the plaque burden in the cortex and hippocampus of the
mouse brain. (D) The level of soluble Ab1-42 was measured using an ELISA kit. STZ treatment significantly increased the levels of Ab1-42 peptide
in APP/PS1 transgenic mouse brain. * p < 0.05, ** p < 0.01 (n = 7).
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Page 7 of 13activation of two major downstream signaling pathways,
the phosphatidylinositol 3-kinase (PI3K) and mitogen-
activated protein kinase (MAPK) pathways [20,40].
GSK3 is one of the key molecules downstream of the
PI3K signaling pathway [41], and ERK and JNK are
major components of two parallel cascades, respectively,
in the MAPK pathways [42]. Importantly, GSK3, ERK
and JNK have all been shown to be involved in the for-
mation of pathomorphological AD hallmarks, such as
Ab plaques [43-45], hyperphosphorylated tau [46-50],
and cerebral neuronal death [51-53].
Therefore, we examined the changes in activities of IR,
GSK3, ERK and JNK in our mouse model. Our data
showed that STZ-induced insulin deficiency reduces the
phosphorylation levels of insulin receptors in the trans-
genic mouse brain. This is consistent with previous
works showing that insulin deficiency inhibits the activ-
ity of its receptors and down-regulates the insulin/IR
signaling pathway [20,33]. Further, we found that insulin
deficiency enhances the activity of GSK3 and JNK, but
not ERK. These findings suggest that STZ-induced insu-
lin deficiency destroys insulin/IR signaling, abrogates the
Figure 6 STZ treatment exacerbates spatial learning impairment in APP/PS1 mice. Morris water maze tests consisted of 2 days of visible
platform training, 5 days of hidden platform testing, and a probe trial 24 h after the last hidden platform test. (A, B) The visible platform tests
showed that no significant differences in escape latency and swimming distances were detected between vehicle and STZ-treated transgenic
mice. (C, D) The hidden platform tests showed that STZ treatment significantly increased both the escape latency and swimming length from
the 2nd to 5th day. (E) The probe trial test showed that administration of STZ significantly reduced the time that mice traveled into the center
of the quadrant, where the hidden platform was previously located. *p < 0.05, **p < 0.01 (n = 7).
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Page 8 of 13downstream GSK3 and JNK signaling pathways, and
leads to the development of AD pathogenesis.
The activation of GSK3, including the a and b iso-
forms, through autophosphorylation has been implicated
in AD pathogenesis [54]. Increased GSK3a activity is
predominantly associated with the processing of APP
and generation of Ab [23], whereas activation of GSK3b
is mainly involved in tau phosphorylation and the for-
mation of NFTs [55-57]. Several studies have shown
that GSK3 is closely linked to the mechanisms by which
STZ-induced dysfunction of insulin cascades promotes
the formation of Ab plaques and NFTs [18,19,33]. Fol-
lowing an icv administration in the STZ-induced insu-
lin-resistant brain state (IRBS) rat model, alterations in
GSK3 proteins have been observed downstream of the
PI3K pathway of the IR signaling cascade in the hippo-
campus [57]. Using a STZ-induced insulin deficiency
APP/PS1 transgenic mouse model, we have shown for
the first time that brain insulin deficiency leads to
enhancement of GSK3a/b activation, increased cerebral
amyloidosis, and exacerbation of behavioral deficits.
Although the mechanism of GSK3 modulation in the
AD brain is far from completely understood, it is rea-
sonable to speculate that the regulation of insulin defi-
ciency in APP processing to the amyloidosis pathway is,
at least partly, through activation of GSK3 signaling.
JNK is a member of MAPK, also known as a stress-
activated protein kinase, and the activation of JNK has
been found in brains of AD patients [58,59]. In vitro
studies have shown that intracellular Ab accumulation
triggers JNK activation, leading to neuronal death
[60,61]. In Tg2576/PS1 double transgenic mice, JNK
activation was associated with age-dependent Ab deposi-
tion, tau phosphorylation, and the loss of synaptophysin
[47,62]. Other reports have demonstrated that BACE1
activation is related to a mechanism involving JNK acti-
vation during oxidative stress [63,64]. Furthermore, JNK
up-regulates phosphorylated Thr668, the main phos-
phorylation site of APP [65], and participates in the
endoproteolytic cleavage of APP by BACE1 [66]. In our
model mice, we showed that STZ-induced insulin defi-
ciency promotes JNK activation in the transgenic mouse
brain. Furthermore, insulin deficiency enhances the
expression level of BACE1 protein. The present data
suggest that there is a close link between the activation
of JNK and BACE1 in the case of insulin deficiency-
induced cerebral amyloidosis.
We demonstrated that insulin-deficient diabetes in
APP/PS1 transgenic mice exacerbated cognitive deficits,
characterized by excessive Ab accumulation and subse-
quent formation of senile plaques. However, it could not
be ruled out that STZ treatment itself leads to impaired
cognitive performance via other mechanisms related to
IR signaling. Previous studies have shown that lithium
a sas p e c i f i cG S K 3i n h i b i t o rm a yp r e v e n tt h ec o g n i t i v e
deficits [67,68]. Thus, GSK3 has critical function for the
induction of memory formation. Also, over-expression
of GSK3b in mice prevents the induction of LTP [69]
and causes a decrease in spatial learning [70]. In addi-
tion, insulin treatment could be essential for improving
cognitive performance. Intranasal insulin could prevent
cognitive decline and GSK3 activation in a mouse model
of type I diabetes [71]. In addition, daily intranasal insu-
lin treatment has been shown to lessen cognition
impairment in patients diagnosed with early AD [72].
Collectively, this research suggests that insulin defi-
ciency likely plays a role in the regulation of AD-asso-
ciated cognitive deficits.
T h ep r e s e n ts t u d yp r o v i d e se v i d e n c ei n d i c a t i n gt h a t
insulin deficiency is able to aggravate Ab-associated
neuropathology and memory deficits in APP/PS1 trans-
genic mouse model. Insulin deficiency could affect the
pathogenesis of AD through mechanisms unrelated to
Ab metabolism. Interestingly, tau hyperphosphorylation
at Thr231 and Ser396 sites was significantly increased in
insulin-deficient APP/PS1 mice (data not shown). Tau
hyperphosphorylation is a key event in the pathogenesis
of AD. In vivo and in vitro studies have shown that
insulin can affect tau phosphorylation through the acti-
vation of GSK3b [18,73]. In addition, the insulin-degrad-
ing enzyme (IDE) plays a critical role in the mechanism
related to insulin deficiency and AD [74]. IDE has been
shown to degrade not only insulin but also a number of
other small proteins, including Ab [75]. Therefore, insu-
lin deficiency may also decrease IDE expression and
cause reduced degradation of Ab thus contribute to
increase in Ab in APP/PS1 mouse brain [33].
Conclusions
Our current study demonstrates that insulin deficiency-
induced impaired insulin signaling, including activation
of its downstream GSK3a/b and JNK pathways, is
related to the activation of the amyloidogenic APP pro-
cessing resulting in increased generation and deposition
of Ab1-42 and spatial memory deficits in the APP/PS1
transgenic mouse brain. The present data indicate that
dysfunction of the insulin signaling pathway during
insulin deficient diabetes contributes to the enhanced
progression of AD.
Methods
Animals and induction of insulin-deficient diabetes
APP/PS1 mice expressing a chimeric mouse/human
APP (Mo/HuAPP695swe) and a mutant human preseni-
lin 1 (PSEN1dE9) were obtained from the Jackson
Laboratory (West Grove, PA, USA). The APP/PS1
mouse was selected because of the high levels of Ab1-42
generation and neuritic plaque formation in the brain,
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Page 9 of 13and relatively early appearance of behavioral deficits in
the water maze test.
Throughout the experiments, APP/PS1 mice were
kept in cages in a controlled environment (22-25 °C,
50% relative humidity, 12 h light/dark cycle) with free
access to food and water throughout the experimental
period of 20 weeks. All animal experiments were per-
formed in accordance with the care and use of medical
laboratory animals (Ministry of Health PR China, 1998)
and the permission of the laboratory animal ethical stan-
dards of China Medical University.
Three-month-old APP/PS1 mice were fasted for 12 h,
and were intraperitoneally (i.p.) injected with STZ (90
mg/kg, Sigma, dissolved in sodium citrate buffer) for con-
secutive 2 days. Age-matched APP/PS1 mice received
citrate buffer only (vehicle control). Mice with non-fast-
ing blood glucose levels higher than 15 mM/L one week
after STZ injection were considered to be diabetic and
used in the later experiments. During the experimental
period, 5 mice in the STZ-treated group died, probably
due to the high blood glucose level and, finally, 7 mice in
the STZ-treated group and 7 mice in the vehicle control
group were used for subsequent experiments at 19-20
weeks after STZ or vehicle treatment.
The body weight and blood glucose levels of the mice
were monitored for 20 weeks. Blood samples were
obtained by tail prick and blood glucose levels were
measured using a portable blood glucose meter (John-
son, m211667, USA). At the 20th week after STZ
administration, blood was extracted from the heart and
the serum insulin level was determined by an Auto-
mated Chemiluminescence System (Bayer, ADIVA
Centaur, USA).
Morris water maze
At the 19th week after STZ treatment, mice were given
b e h a v i o r a lt e s t sw i t haM o r r i sw a t e rm a z ef o rc o n s e c u -
tive 8 days, including visible platform training, a naviga-
tion test and probe trial, as previously described with
few modifications [76]. In brief, mice were trained indi-
vidually for 2 days (3 trials with an interval of 30 min)
to find the visible escape platform. At the 3rd-7th day,
the platform was placed just below the water surface for
the place navigation test, and each mouse was subjected
to 3 trials per day at an interval of 1 min. For each trial,
the latency and the path length by which the mouse
found the hidden platform were recorded. At the 8th
day, the platform was removed from the water for the
probe trial. The number of times that each mouse
crossed the center of the quadrant (where the platform
was previously located) at an interval of 1 min was
recorded. Finally, data on the escape latency, the path
length and the number of passing times for the STZ-
and vehicle-treated mice were compared and analyzed
statistically with a computer program (ZH0065, Zhen-
ghua Bio-equipments, PR China).
Tissue preparation
After behavioral tests, mice were given an overdose of
phenobarbital, and the blood was extracted from the
heart for serum insulin measurement. Then, the mice
were sacrificed by decapitation, and the brains were
rapidly removed and cut sagittally into left and right
hemispheres on an ice-cooled board. The right hemi-
sphere was fixed in 4% paraformaldehyde and routine
paraffin sections (7 μm) were prepared for morphologi-
cal analysis. The hippocampus and cerebral cortex were
dissected from the left hemisphere and stored at -80°C
for sandwich enzyme-linked immunosorbent assay
(ELISA) and Western blot analyses.
Immunohistochemistry and image analysis of plaque
pathology
Ab immunohistochemical staining was performed to
analyze the distribution of Ab plaques in the APP/PS1
mouse brain. Briefly, paraffin sections were dewaxed,
rehydrated and treated in 0.1 M Tris-HCl buffer (TBS,
pH 7.4) containing 3% hydrogen peroxide (H2O2)f o r1 0
min. After washing with TBS, sections were boiled in
citric acid buffer for 5 min in a microwave oven. The
sections were then rinsed, treated with 5% bovine serum
albumin for 30 min, and incubated overnight with
mouse anti-Ab antibody (1:500, Sigma) at 4°C. After rin-
sing, sections were incubated with biotinylated goat
anti-mouse IgG (1:200) for 1 h, followed by streptavidin
peroxidase for 1 h at room temperature. After rinsing,
the sections were treated with 0.025% 3,3-diaminobenzi-
dine plus 0.0033% H2O2 in TBS for 10 min. The sec-
tions were dehydrated, cleared, covered and examined
under a light microscope equipped with a digital camera
(Olympus; AX70U-Photo, Japan). Control sections were
treated with identical solutions but without primary
antibody.
To assess the plaque number and Ab burden in the
cortex and hippocampus, 5 sections with the same refer-
ence position were selected from each mouse (n = 7).
The number of plaques and the percentage of the total
area of Ab-positive areas compared with the total area
of the cortex and hippocampus were quantified (in
square micrometers). The data were analyzed with the
image analysis system (Image-Pro Plus 6.0).
Western blotting
Brain samples were minced into small pieces and homo-
genized in lysis buffer containing 150 mM sodium
chloride, 50 mM Tris-hydrochloride, 1% Nonidet P-40,
0.25% sodium deoxycholate, 0.1% SDS, 1 mM phe-
nylme-thylsulfonyl fluoride (PMSF), 10 mg/ml leupeptin,
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night at 4°C. The homogenate was centrifuged at 12,000
rpm for 30 min and the supernatant was divided into
aliquots and frozen at -80°C. The total protein extract
(60 μg) was separated on SDS-polyacrylamide gels and
then transferred onto polyvinylidene difluoride mem-
branes (Millipore, CA). Nonspecific binding sites on the
membrane were blocked by 5% bovine serum albumin
in 0.1% TBS/Tween-20 (TBST) for 1 h. The membranes
were then incubated overnight at 4°C in specific primary
antibodies: rabbit anti-APP695 (1:2000, Chemicon), rab-
bit anti-ADAM10 (1:1000, Millipore), rabbit anti-BACE1
(1:1000, Sigma), rabbit anti-presenilin 1 (PS1) (1:800,
Millipore), rabbit anti-C-terminal fragments of APP
(CTFs) (1:1000, Sigma-Aldrich), mouse anti-sAPPa
(1:500, Immuno-Biological Laboratories), mouse anti-
sAPPb (1:500, Immuno-Biological Laboratories), phos-
pho-APP (Thr668) (1:500, Cell Signaling Technology),
rabbit anti-phospho-IR (Tyr972) (1:500, Millipore), rab-
bit anti-IR (1: 500, Millipore), rabbit anti-phospho-
GSK3a (Ser21) (1:1000, Cell Signaling Technology), rab-
bit anti-GSK3a (1:1000, Cell Signaling Technology), rab-
bit anti-phospho-GSK3b (Ser9) (1:1000, Cell Signaling
Technology), rabbit anti-GSK3b (1:1000, Cell Signaling
Technology), rabbit anti-phospho-ERK1/2 (Thr202/
Tyr204) (1:1000, Cell Signaling Technology), rabbit anti-
ERK 1/2 (1:1000, Cell Signaling Technology), rabbit
anti-phospho-JNK (Thr183/Tyr185) (1:1000, Cell Signal-
ing Technology), rabbit anti-JNK (1:1000, Cell Signaling
Technology) and mouse b-actin (1:5000, Santa Cruz
Biotechnology).
After washing with TBST, the membranes were incu-
bated with horseradish peroxide-conjugated second anti-
body (1:5000; Santa Cruz Biotechnology) for 1 h at
room temperature. Immunoreactive bands were visua-
lized using the Super Signal West Pico Chemi-lumines-
cent Substrate (Pierce Biotechnology, Rockford, IL)
using Chem Doc XRS with Quantity One software
(BioRad, USA). The bands were scanned and the inten-
sities of the bands were measured using Image-pro Plus
6.0 analysis software.
RT-PCR
Tissue homogenates of the cortex of APP/PS1 mice trea-
ted with STZ and vehicle controls were collected. Total
RNA was isolated using Trizol reagent (Invitrogen) and
the RNA concentration was determined by measuring the
absorbance at 260 nm. The total RNA of each sample was
first reverse-transcribed into cDNA using EasyScriptTM
Two-Step RT-PCR SuperMix (TransGen Biotech). PCR
amplification was performed with reagents from TransGen
Biotech. The Human APP cDNA was amplfied using
primers as follows: 5’-GACTGACCACTCGACCAGGT
TCTG-3’ (upstream), 5’-CTTGAAGTTGGATTCTCA-
TACCG-3’ (downstream); GAPDH: 5’-TTCAACGGCA-
CAGTCAAGG-3’ (upstream), 5’-CACCAGTGGATGC
AGGGAT-3’ (downstream). Amplification was performed
as follows: APP: 35 cycles of 95°C for 30 s, 62°C for 30 s
and 72°C for 30 s; GAPDH: 30 cycles of 95°C for 45 s,
58°C for 45 s, and 72°C for 60 s. The PCR products were
normalized in relation to standards of GAPDH mRNA.
Sandwich ELISA
Brain samples from APP/PS1 transgenic mice were homo-
genized in 5.0 M guanidine buffer (diluted in standard
dilution) and centrifuged for 30 min at 4°C. The superna-
tants were then loaded onto 96-well plates and the level of
soluble Ab1-42 was determined using an ELISA kit (Invi-
trogen) in accordance with the instructions of the manu-
facturers. The absorbance was recorded at 450 nm using a
96-well plate reader.
Statistical analysis
All values are expressed as mean ± standard deviation
(SD). Differences between groups were analyzed by Stu-
dent’s t-test between STZ-induced insulin deficient dia-
betic AD model mice and vehicle controls. All data
were analyzed using SPSS software, and differences were
considered significant at p < 0.05.
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